Home

Převléknout se zklamat Neplatný events per 100 patient years komentátor navzdory Pozorný

Cleveland Clinic Journal of Medicine : September 2021 - CD
Cleveland Clinic Journal of Medicine : September 2021 - CD

Primary end point in normotensive and hypertensive patients at baseline (events  per 100 patient-years of follow-up) Primary end point Nifedipine Placebo. -  ppt download
Primary end point in normotensive and hypertensive patients at baseline (events per 100 patient-years of follow-up) Primary end point Nifedipine Placebo. - ppt download

Exposure-adjusted rates (per 100 patient-years) of common... | Download  Table
Exposure-adjusted rates (per 100 patient-years) of common... | Download Table

ncidence of severe hypoglycemic episodes per 100 patient-years in... |  Download Scientific Diagram
ncidence of severe hypoglycemic episodes per 100 patient-years in... | Download Scientific Diagram

Tezepelumab shows long-term safety, efficacy for severe asthma
Tezepelumab shows long-term safety, efficacy for severe asthma

Event rates per 100 patient-years follow-up (number of events) | Download  Table
Event rates per 100 patient-years follow-up (number of events) | Download Table

Cleveland Clinic Journal of Medicine : March 2023 - CD
Cleveland Clinic Journal of Medicine : March 2023 - CD

Prevention Of Arterial And Venous Vascular Events In Symptomatic Peripheral  Arterial Disease Patients After Lower Extremity Revascularization in the  VOYAGER PAD trial: Dual Anticoagulant/Antiplatelet Regimen Vs Antiplatelet  Therapy Alone - ISTH Congress
Prevention Of Arterial And Venous Vascular Events In Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD trial: Dual Anticoagulant/Antiplatelet Regimen Vs Antiplatelet Therapy Alone - ISTH Congress

Rates (per 100 patient years) for individual end-points. | Download Table
Rates (per 100 patient years) for individual end-points. | Download Table

Incidence rates of the different events per 100 person-years by... |  Download Scientific Diagram
Incidence rates of the different events per 100 person-years by... | Download Scientific Diagram

Real-world safety and effectiveness of rivaroxaban using Japan-specific  dosage during long-term follow-up in patients with atrial fibrillation:  XAPASS | PLOS ONE
Real-world safety and effectiveness of rivaroxaban using Japan-specific dosage during long-term follow-up in patients with atrial fibrillation: XAPASS | PLOS ONE

Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with  Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years  of Exposure | SpringerLink
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis: Results from Greater Than 17,000 Patient-Years of Exposure | SpringerLink

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis  with over 2 Years Median Time in Treatment | The Journal of Rheumatology
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment | The Journal of Rheumatology

Treatment-emergent adverse events per 100 patient-years by years of... |  Download Scientific Diagram
Treatment-emergent adverse events per 100 patient-years by years of... | Download Scientific Diagram

Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis |  NEJM
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis | NEJM

Transcatheter Closure of Patent Foramen Ovale in Older Patients With  Cryptogenic Thromboembolic Events | Circulation: Cardiovascular  Interventions
Transcatheter Closure of Patent Foramen Ovale in Older Patients With Cryptogenic Thromboembolic Events | Circulation: Cardiovascular Interventions

Exposure-adjusted rates (per 100 patient-years) of common... | Download  Table
Exposure-adjusted rates (per 100 patient-years) of common... | Download Table

Event rate per 100 patient-years of adverse clinical events for each... |  Download Scientific Diagram
Event rate per 100 patient-years of adverse clinical events for each... | Download Scientific Diagram

exposure-adjusted Aes through week 52 (event rate per 100 patient-years) |  Download Table
exposure-adjusted Aes through week 52 (event rate per 100 patient-years) | Download Table

Event rates and crude incidence rates per 100 patient years. | Download  Scientific Diagram
Event rates and crude incidence rates per 100 patient years. | Download Scientific Diagram